Merck (MRK) Operating Margin (2009 - 2026)
Merck (MRK) posted quarterly Operating Margin of 47.46% for Q1 2026, down 6345.0% YoY from 0.76% in Q1 2025, and down 265.23% sequentially from 12.99% in Q4 2025.
Merck (MRK) Operating Margin (2009 - 2026) Analysis & Trends
Merck has disclosed Operating Margin across 18 years of filings, most recently posting 47.46% for Q1 2026.
- In Q1 2026, Operating Margin fell 6345.0% year-over-year to 47.46%; the TTM figure through Mar 2026 stood at 8.41% (down 1638.0% YoY), while the FY2025 annual figure was 7.21%, down 19.0% from the prior year.
- Operating Margin slipped to 47.46% in Q1 2026, from 12.99% in the prior quarter.
- Over the last five years, Operating Margin for MRK reached as high as 16.73% in Q3 2025 and fell as low as 62.25% in Q2 2023.
- The 5-year median for Operating Margin is 0.06% (2024), against an average of 5.39%.
- Annual changes were most pronounced in 2023 — Operating Margin slumped 6411 bps — and 2024, when it surged 7628 bps.
- A 5-year view of Operating Margin shows it stood at 2.66% in 2022, then slumped by 1430 bps to 40.72% in 2023, then soared by 105 bps to 2.19% in 2024, then slumped by 694 bps to 12.99% in 2025, then tumbled by 265 bps to 47.46% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 47.46%, 12.99%, and 16.73% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 47.98% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 26.44% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 26.60% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 29.51% |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -286.83% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | -11.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.46% |
| Dec 31, 2025 | -12.99% |
| Sep 30, 2025 | 16.73% |
| Jun 30, 2025 | 9.12% |
| Mar 31, 2025 | 16.00% |
| Dec 31, 2024 | 2.19% |
| Sep 30, 2024 | 0.06% |
| Jun 30, 2024 | 14.03% |
| Mar 31, 2024 | 13.50% |
| Dec 31, 2023 | -40.72% |
| Sep 30, 2023 | 8.50% |
| Jun 30, 2023 | -62.25% |
| Mar 31, 2023 | -1.91% |
| Dec 31, 2022 | -2.66% |
| Sep 30, 2022 | -2.35% |
| Jun 30, 2022 | 1.86% |
| Mar 31, 2022 | -3.26% |
| Dec 31, 2021 | 0.26% |
| Sep 30, 2021 | 13.81% |
| Jun 30, 2021 | -12.16% |